글로벌 간성뇌병증 치료 시장 - 2028년까지의 산업 동향 및 예측

간성뇌병증 치료 시장의 시장 분석 및 통찰력

Data Bridge Market Research는 간성 뇌병증 치료가 2021-2028년 예측 기간 동안 약 5.325%의 CAGR을 보일 것이라고 분석했습니다. 표적 치료 모드에 대한 수요 증가, 신약 및 치료법 개발을 위한 연구 개발 활동 급증, 만성 질환 유병률 증가, 의료 인프라 개발 지출 증가가 간성 뇌병증 치료 시장 성장에 기여하는 주요 요인입니다.

간성 뇌병증은 급성 간부전과 관련된 뇌 질환입니다. 일반적으로 간경변증 환자와 말기 간 질환 환자에게 진단됩니다. 간성 뇌병증은 뇌 기능 장애와 지적 장애로 인해 성격 변화를 초래하고 의식을 잃으며 결국 생명을 위협하는 합병증으로 이어집니다.

규제 당국의 특별 지정 증가와 간성 뇌병증의 유병률 증가는 시장 성장을 촉진하는 주요 요인입니다. 의료 인프라 개발에 대한 지출 증가, 충족되지 않은 치료 요구 증가, 개선되고 효과적인 치료법에 대한 필요성 증가, 전 세계적으로 신경계 질환 및 간경변의 급증, 시장 참여자 간의 전략적 협력 비율의 급증은 시장 성장을 촉진하는 다른 요인입니다. ANDA(약식 신약 신청) 제출 증가는 수익성 있는 시장 성장 기회를 창출할 또 다른 간접적인 결정 요인입니다.

However, dearth of skilled medical professionals and unfavourable reimbursement scenario in the developing and under developed economies will pose a major challenge to the market growth. Also, high costs associated with research and development proficiencies and with the treatment will further derail the market growth rate.

This hepatic encephalopathy treatment market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on hepatic encephalopathy treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Hepatic Encephalopathy Treatment Market Scope and Market Size

The hepatic encephalopathy treatment market is segmented on the basis of drug class, type, diagnosis, stages, treatment, route of administration, end users and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

• On the basis of drug class, the hepatic encephalopathy treatment market is segmented into antibiotics, laxatives, L-ornithine L-aspartate and others.
• On the basis of type, the hepatic encephalopathy treatment market is segmented into acute fulminant viral hepatitis, toxic hepatitis and others.
• On the basis of diagnosis, the hepatic encephalopathy treatment market is segmented into blood tests, CT scan, liver functioning tests (LFT) and others.  
• On the basis of stages, the hepatic encephalopathy treatment market is segmented into stage 0, stage 1, stage 3 and others.
• On the basis of treatment, the hepatic encephalopathy treatment market is segmented into medication, surgery and others.
• On the basis of route of administration, the hepatic encephalopathy treatment market is segmented into oral, injectable, intravenous, rectal and others.
• On the basis of end users, the hepatic encephalopathy treatment market is segmented into hospitals, home care, speciality clinics, and others.
• On the basis of distribution channel, the hepatic encephalopathy treatment market is segmented into hospital pharmacy, online pharmacy, retail pharmacy and others.

Hepatic Encephalopathy Treatment Market Country Level Analysis

The hepatic encephalopathy treatment market is segmented on the basis of drug class, type, diagnosis, stages, treatment, route of administration, end users and distribution channel.

The countries covered in the hepatic encephalopathy treatment market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

North America dominates the hepatic encephalopathy treatment market owing to the earliest adoption of innovative technologies, increasing prevalence of liver diseases in the region and growing research and development capacities. Asia-Pacific is projected to undergo substantial gains during the forecast period and score the highest CAGR. This is because of the rising expenditure to develop healthcare infrastructure, growing cases of neurological disorders and increase in the research and development activities for the treatment and management of liver diseases.

The country section of the hepatic encephalopathy treatment market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

The hepatic encephalopathy treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the hepatic encephalopathy treatment market in the growth period.

Competitive Landscape and Hepatic Encephalopathy Treatment Market Share Analysis

간성 뇌병증 치료 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우세입니다. 위에 제공된 데이터 포인트는 간성 뇌병증 치료 시장과 관련된 회사의 초점에만 관련이 있습니다.

간성 뇌병증 치료 시장 보고서에 포함된 주요 기업으로는 Mallinckrodt, Lupin., Salix Pharmaceuticals, Norgine, ASKA Pharmaceutical Co., Ltd., Bausch Health, Sobi, Inc., Umecrine, Kannalife Sciences, Inc., Ferring BV, Merck KGaA, Amgen Inc., Pfizer Inc., GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Merck & Co., Inc., Janssen Global Services, LLC, Eisai Co., Ltd., Johnson & Johnson Services, Inc., AbbVie Inc., Hikma Pharmaceuticals PLC 등이 있으며, 국내 및 글로벌 기업도 있습니다. 시장 점유율 데이터는 글로벌, 북미, 유럽, 아시아 태평양(APAC), 중동 및 아프리카(MEA) 및 남미에 대해 개별적으로 제공됩니다. DBMR 분석가는 경쟁 우위를 이해하고 각 경쟁자에 대한 경쟁 분석을 개별적으로 제공합니다.

SKU-50418